and evidence of monitoring
Wharton S, Lau DCW, Vallis M, et al
Close monitoring of blood glucose is essential when co-administering these medications. Synjardy Weight Management While some patients may experience modest weight loss, Synjardy is not a weight-loss drug
VPA treatment enhanced norepinephrine uptake and also induced expression of GAP-43 and Bcl-2, the genes controlled by ERK pathway (Yuan, 2001)
Additional warnings in the FDA prescribing information include: severe gastrointestinal adverse reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, hypoglycemia risk when used with insulin or insulin secretagogues, diabetic retinopathy complications and vision changes in patients with type 2 diabetes, depression or mood changes requiring clinical monitoring, and pulmonary aspiration risk during general anesthesia or deep sedation
18 The prescribing information for oral semaglutide notes that the most common side effects with use include nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation